Comparison between DEE Development Engineers IPO and Emcure Pharmaceuticals IPO.
DEE Development Engineers IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Emcure Pharmaceuticals IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of DEE Development Engineers IPO is up to ₹418.01 Cr whereas the issue size of the Emcure Pharmaceuticals IPO is up to ₹1,952.03 Cr. The final issue price of DEE Development Engineers IPO is ₹203.00 per share and of Emcure Pharmaceuticals IPO is ₹1,008.00 per share.
| DEE Development Engineers IPO | Emcure Pharmaceuticals IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹193.00 per share | ₹960.00 per share |
| Issue Price (Upper) | ₹203.00 per share | ₹1,008.00 per share |
| Issue Price (Final) | ₹203.00 per share | ₹1,008.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ₹19.00 per share | ₹90.00 per share |
| Market Lot Size | 73 shares | 14 shares |
| Fresh Issue Size | 1,60,14,938 shares | 79,46,231 shares |
| Fresh Issue Size (Amount) | up to ₹325.02 Cr | up to ₹800.58 Cr |
| OFS Issue Size | 45,82,000 shares | 1,14,28,839 shares |
| OFS Issue Size (Amount) | up to ₹92.99 Cr | up to ₹1,151.45 Cr |
| Issue Size Total | 2,05,96,938 shares | 1,93,75,070 shares |
| Issue Size Total (Amount) | up to ₹418.01 Cr | up to ₹1,952.03 Cr |
DEE Development Engineers IPO opens on Jun 19, 2024, while Emcure Pharmaceuticals IPO opens on Jul 03, 2024. The closing date of DEE Development Engineers IPO and Emcure Pharmaceuticals IPO is Jun 21, 2024, and Jul 05, 2024, respectively.
| DEE Development Engineers IPO | Emcure Pharmaceuticals IPO | |
|---|---|---|
| Anchor Bid Date | Jun 18, 2024 | Jul 02, 2024 |
| Issue Open | Jun 19, 2024 | Jul 03, 2024 |
| Issue Close | Jun 21, 2024 | Jul 05, 2024 |
| Basis Of Allotment (Tentative) | Jun 24, 2024 | Jul 08, 2024 |
| Initiation of Refunds (Tentative) | Jun 25, 2024 | Jul 09, 2024 |
| Credit of Share (Tentative) | Jun 25, 2024 | Jul 09, 2024 |
| Listing date (Tentative) | Jun 26, 2024 | Jul 10, 2024 |
| Anchor Lockin End date 1 | Jul 24, 2024 | Aug 07, 2024 |
| Anchor Lockin End date 2 | Sep 22, 2024 | Oct 06, 2024 |
DEE Development Engineers IPO P/E ratio is 83, as compared to Emcure Pharmaceuticals IPO P/E ratio of 34.55.
| DEE Development Engineers IPO | Emcure Pharmaceuticals IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 100.00 | 83.21 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 78.08 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 83 | 34.55 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹1401.69 Cr. | ₹19029.89 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 16.90% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 3.91% | 19.37% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.85 | 0.67 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹2.45 | ₹29.17 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 3.35% | 16.87% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the DEE Development Engineers IPO Retail Individual Investors (RII) are offered 71,89,907 shares while in Emcure Pharmaceuticals IPO retail investors are offered 71,89,907 shares. Qualified Institutional Buyers (QIB) are offered 41,08,518 shares in DEE Development Engineers IPO and 38,53,234 shares in Emcure Pharmaceuticals IPO.
| DEE Development Engineers IPO | Emcure Pharmaceuticals IPO | |
|---|---|---|
| Anchor Investor Reservation | 61,62,777 shares | 57,79,850 shares |
| Market Maker Reservation | ||
| QIB | 41,08,518 shares | 38,53,234 shares |
| NII | 30,81,389 shares | 28,89,926 shares |
| RII | 71,89,907 shares | 67,43,160 shares |
| Employee | 54,347 shares | 1,08,900 shares |
| Others | ||
| Total | 2,05,96,938 shares | 1,93,75,070 shares |
DEE Development Engineers IPO subscribed 103.03x in total, whereas Emcure Pharmaceuticals IPO subscribed 67.87x.
| DEE Development Engineers IPO | Emcure Pharmaceuticals IPO | |
|---|---|---|
| QIB (times) | 206.54x | 191.24x |
| NII (times) | 149.38x | 49.32x |
| Big NII (times) | 165.71x | 54.90x |
| Small NII (times) | 116.73x | 38.16x |
| RII (times) | 23.66x | 7.36x |
| Employee (times) | 8.81x | |
| Other (times) | ||
| Total (times) | 103.03x | 67.87x |
